Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Trial Profile

A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baclofen/naltrexone/sorbitol (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Adverse reactions
  • Sponsors Pharnext
  • Most Recent Events

    • 01 Sep 2016 According to Pharnext media release,data from this trial will be presented at the 6th international Charcot-Marie-Tooth and Related neuropathy Consortium (CMTR) conference.
    • 30 Jun 2015 Baseline analysis presented at the 2015 Peripheral Nerve Society (PNS) Biennial Meeting, according to a Pharnext media release.
    • 17 Dec 2014 According to a Pharnext Media Release, results were published in Orphanet Journal of Rare Diseases journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top